By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Genticel 

Prologue-Biotech
Rue Pierre et Marie Curie BP 28262
Cedex  Labège-Innopole  31682  France
Phone: 33-5-6128-7060 Fax: 33-5-6128-7069


SEARCH JOBS








Company News
Genticel Successfully Completes Determining Milestone In Partnership With Serum Institute of India, Ltd. Regarding Use Of GTL003 In Multivalent Vaccines 12/1/2016 7:47:47 AM
Genticel's HPV Candidate Did Not Meet Primary Endpoint in Phase II Study 1/27/2016 11:41:43 AM
Genticel To Evaluate Roche Molecular Systems (RHHBF.PK)’ cobas HPV Test In Preparation For PhIII Program Of GTL001 1/7/2016 8:32:03 AM
Genticel Announces First Patient Treated In U.S. Phase 1 Clinical Trial Of GTL001, Company's Therapeutic Vaccine Candidate Against HPV 16/18 Infections 10/29/2015 12:53:08 PM
Genticel Presents First Half 2015 Financial Results, Operational Progress & Outlook 9/22/2015 8:09:18 AM
U.S. Patent Granted For Use Of Genticel's Antigen Delivery Vectors In Combination Therapy To Treat Cancer 9/8/2015 8:15:38 AM
Independent Data Safety Monitoring Board Recommends Continuation Per Protocol Of Genticel's Phase II Clinical Trial Of GTL001 (Procervix), Company's First-In-Class HPV Therapeutic Vaccine Candidate 7/8/2015 7:12:35 AM
Independent Data Safety Monitoring Board Recommends Continuation, Per Protocol, Of Genticel’s Phase 2 Clinical Trial Of GTL001 (Procervix), Company’s First-In-Class HPV Therapeutic Vaccine Candidate 7/7/2015 3:15:43 PM
Genticel Receives FDA Clearance Of IND Application For U.S. Phase I Clinical Trial Of GTL001 (Procervix), Company's First-In-Class HPV Therapeutic Vaccine Candidate 6/16/2015 7:18:06 AM
Genticel Announces Positive Preclinical Proof Of Concept Results Of GTL002, Its New Multivalent HPV Therapeutic Vaccine Candidate Based On Company's Versatile Vaxiclase Platform 6/1/2015 9:12:44 AM
1234
//-->